Novo Nordisk's shares fell over 9% following the ZEUS trial results, where the drug ziltivekimab lowered inflammation markers but did not reduce major cardiovascular events. The phase 3 trial showed a hazard ratio of 0.99 versus placebo, with higher serious infections in the treatment group but no difference in overall mortality. Despite this setback, Novo Nordisk will continue two other cardiovascular trials, HERMES and ARTEMIS, with results expected in early 2027. The company maintains its 2026 profit forecast and will record a non-cash impairment in Q3 2026 due to the trial outcome.
The global SaaS market, valued at $310-330 billion in 2025, is projected to nearly double to $600-650 billion by 2030, driven by cloud adoption, AI integration, and product-led growth strategies. SaaS companies are shifting marketing investments towa...
AbbVie reported adjusted diluted EPS of $3.65 for Q2 2026, surpassing analyst expectations of $3.60, and achieved revenues of $16.99 billion, exceeding forecasts of $16.78 billion. Strong growth in its Immunology and Neuroscience segments drove this ...
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...
Deutsche Bank downgraded Roblox stock to Hold with a price target of $38, signaling a potential 22% drop from current levels. Roblox reported mixed Q2 results with a smaller-than-expected loss but revenues slightly below estimates. The company expect...
Citigroup increased its price target for PTC Inc. to $141 from $127, citing strong momentum in artificial intelligence and a 9.1% year-over-year growth in Annual Recurring Revenue (ARR) to $2.448 billion. This comes despite PTC's mixed third-quarter ...
